Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice

Virology Journal

Volumn 10, Issue , 2013, Pages

  Xu, Xian Hua ^a   Li, Gai Li ^a   Qin, Yang ^a   Li, Qiang ^a   He, Fa Qun ^a   Li, Jin Ye ^a   Pan, Quan Rong ^a   Deng, Jie Yin ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Adefovir; Chronic hepatitis B; Combination therapy; Entecavir; Multiple failures; Resistance

Indexed keywords

ADEFOVIR; CREATINE KINASE; CREATININE; ENTECAVIR; HEPATITIS B ANTIGEN; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; HEPATITIS B, CHRONIC; MIDDLE AGED; PROCEDURES; SALVAGE THERAPY; VIRUS LOAD;

HEPATITIS B VIRUS;

ADENINE; ADULT; ANTIVIRAL AGENTS; CREATINE KINASE; CREATININE; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84878008804     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-162     Document Type: Article

References (22)

1. Impact of therapy on the outcome of chronic hepatitis B. Liaw YF, Liver Int 2013 33 Suppl 1 111 115 23286854
2. Treatment of chronic hepatitis B: Evolution over two decades. Yuen M-F, Lai C-L, Journal of gastroenterology and hepatology 2011 26 Suppl 1 138 181 21199525
3. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana R, Marrero J, Licari T, Lok A, Hepatology 2011 53 1854 1917 10.1002/hep.24318 21618260
4. Hepatitis B virus resistance to nucleos(t)ide analogues. Zoulim F, Locarnini S, Gastroenterology 2009 137 1593 1608 1591-1592 10.1053/j.gastro. 2009.08.063 19737565
5. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. Vassiliadis T, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Journal of gastroenterology and hepatology 2010 25 54 114 10.1111/j.1440-1746.2009.05952.x 19780875
6. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY, J Med Virol 2013 85 55 64 10.1002/jmv.23440 23096938
7. Prevention and management of drug resistant hepatitis B virus infections. Wang C, Fan R, Sun J, Hou J, J Gastroenterol Hepatol 2012 27 1432 1440 10.1111/j.1440-1746.2012.07198.x 22694205
8. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Ryu H, Lee J, Ahn S, Kim DY, Lee M, Han K-H, Chon C, Park J, Journal of medical virology 2010 82 1835 1877 10.1002/jmv.21898 20872709
9. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H, World J Gastroenterol 2012 18 7149 7157 10.3748/wjg.v18.i48.7149 23326119
10. New advances in chronic hepatitis B. Tujios SR, Lee WM, Curr Opin Gastroenterol 2012 28 193 197 10.1097/MOG.0b013e32835297ef 22450894
11. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. Kim S, Cheong J, Lee D, Lee M, Hong S, Kim S-O, Cho S, Journal of medical virology 2012 84 18 43 10.1002/jmv.22227 22028068
12. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Chen E-Q, Wang L-C, Lei J, Xu L, Tang H, Virology journal 2009 6 163 10.1186/1743-422X-6-163 19818142
13. High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. Chae HB, Kim MJ, Seo EG, Choi YH, Lee HS, Han JH, Yoon SM, Park SM, Youn SJ, Korean J Hepatol 2012 18 75 83 10.3350/kjhep.2012.18.1.75 22511906
14. Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. Chen EQ, Zhou TY, Bai L, Wang JR, Yan LB, Liang LB, Tang H, Antivir Ther 2012 17 973 979 10.3851/IMP2190 22728692
15. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Seto WK, Liu K, Fung J, Wong DK, Yuen JC, Hung IF, Lai CL, Yuen MF, Antivir Ther 2012 17 1255 1262 10.3851/IMP2335 22951420
16. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance. Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Du Jeong I, Bang SJ, Park NH, Antivir Ther 2012 17 387 394 22293395
17. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM, Antivir Ther 2012 17 701 709 10.3851/IMP2074 22358132
18. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Zoulim F, Locarnini S, Liver Int 2013 33 Suppl 1 116 124 23286855
19. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H, Shen L, Huang C, Shen W, Huang Z, Intern Med 2012 51 1509 1515 10.2169/internalmedicine.51.7329 22728482
20. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ, J Hepatol 2010 53 449 454 10.1016/j.jhep.2010.03.020 20646776
21. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ, Antimicrob Agents Chemother 2012 56 2941 2947 10.1128/AAC.00338-12 22430972
22. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Gastroenterology 2006 130 2039 2049 10.1053/j.gastro.2006.04.007 16762627